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Abstract 
Background: Outcomes after stroke in those with diabetes are not well characterized, especially 
by sex and age. We sought to calculate the sex- and age-specific risk of cardiovascular outcomes 
after ischemic stroke among those with diabetes.   
Methods: Using population-based demographic and administrative health care databases in 
Ontario, Canada, all patients with diabetes hospitalized with index ischemic stroke between April 
1, 2002 and March 31, 2012 were followed for death, stroke, and myocardial infarction (MI).  
Kaplan-Meier survival analysis and Fine-Gray competing risk models estimated hazards of 
outcomes by sex and age, unadjusted and adjusted for demographics and vascular risk factors.   
Results:  Among 25495 diabetic patients with index ischemic stroke, incidence of death was 
higher in women than in men (14.08 per 100 person-years [95% CI 13.73-14.44] vs. 11.89 
[11.60-12.19]), but was lower after adjustment for age and other risk factors (adjusted hazard 
ratio [HR] 0.95 [0.92-0.99]).  Recurrent stroke incidence was similar by sex, but men were more 
likely to be readmitted for MI (1.99 per 100 person-years [1.89-2.10] vs 1.58 [1.49-1.68] among 
females).  In multivariable models, females had a lower risk of readmission for any event (HR 
0.96 [95% CI 0.93-0.99]).  
Conclusions: In this large, population-based, retrospective study among diabetic patients with 
index stroke, women had higher unadjusted death rate but lower unadjusted incidence of MI.  In 
adjusted models, females had a lower death rate compared to males, although the increased risk 
of MI among males persisted. These findings confirm and quantify sex differences in outcomes 
after stroke in patients with diabetes. 
1 
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INTRODUCTION 1 
There are sex differences in the risk of cardiovascular disease in people with diabetes. Compared 2 
to men, women with diabetes have a 40% higher risk of incident coronary heart disease1 and 3 
27% higher risk of stroke.2 However, sex differences in outcomes in diabetic patients following 4 
an incident event are unclear, with conflicting findings in previous studies.3, 4 Sex differences 5 
have been demonstrated for myocardial infarction (MI) 5, 6 and other cardiovascular disease,7 but 6 
data on sex differences in outcomes among people with diabetes after incident stroke are less 7 
consistent. Relatively small studies have reported higher in-hospital mortality8 and long-term 8 
mortality9 for diabetic females, but others have shown no association of sex and outcomes10, 11 9 
Furthermore, prior studies mostly examined mortality and did not measure readmission rates. 10 
Studies to date have not adequately assessed for socioeconomic status and medication usage, 11 
which may confound the relationship between sex and outcomes. There is a lack of reliable 12 
population-based data on the effect of sex on mortality and readmissions among diabetic patients 13 
following an incident stroke. 14 
The objective of this analysis was to examine differences in cardiovascular events and 15 
mortality by sex and age among those with diabetes after ischemic stroke in Ontario. We 16 
hypothesized that women had higher mortality compared to men and that the readmission risk for 17 
cardiovascular events differed by sex.  18 
 19 
METHODS 20 
We conducted a retrospective analysis of a population-based sample using linked administrative 21 
databases in Ontario, Canada’s most populous province.  Because of government-funded health 22 
insurance for all permanent residents of Ontario, data were available on the entire population.  23 
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The Ontario Registered Persons Database (RPDB) provided data on mortality after stroke, and 1 
the Canadian Institute for Health Information Discharge Abstract Database (CIHI-DAD) 2 
identified readmissions for stroke and myocardial infarction (MI).  CIHI-DAD contains <25 3 
diagnosis fields for admissions to Ontario hospitals and uses the International Classification of 4 
Diseases, 10th revision coding system (ICD-10) for the year 2002 onwards. In previous studies 5 
of CIHI-DAD in Canadian hospitals, there was high positive predictive value (85% for ischemic 6 
stroke, 98% for intracerebral hemorrhage, and 91% for subarachnoid hemorrhage) and Kappa of 7 
0.89 for agreement between coder and researcher using ICD-10 codes.12 The Ontario Drug 8 
Benefits (ODB) database provided information on prescriptions filled by all residents aged >65 9 
years.  These databases were linked via a unique, encoded identifier and analyzed at the Institute 10 
for Clinical Evaluative Sciences (ICES). The institutional ethics review board of Sunnybrook 11 
Health Sciences Centre approved this study. 12 
 13 
Sample selection 14 
We included those with an index ischemic stroke admission during the study period in CIHI-15 
DAD, identified with any of the following ICD-10 codes: I63 (excluding I63.6), I64, H34.0, or 16 
H34.1 in the “most responsible diagnosis” field, which has been shown to have 92% accuracy for 17 
stroke diagnosis.13 We identified diagnosis of diabetes prior to or at the time of the index 18 
ischemic stroke admission by linking to the Ontario Diabetes Database (ODD), which has a 19 
sensitivity of 91% and specificity of 99%.14 We limited the sample to those with ischemic stroke 20 
and diabetes who were >18 years of age at the time of admission.  Index stroke admissions from 21 
4/1/2002 to 3/312012 were included, with maximum follow-up to 3/31/2013.   22 
 23 
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Baseline assessment 1 
Age was calculated as age at admission for index ischemic stroke.  Income was estimated using 2 
neighborhood-level household income and was categorized into quintiles.  Duration of diabetes 3 
was calculated by using the diagnosis date in the ODD and was categorized into: 0 to <3, 3 to <6, 4 
and >6 years.  Duration of Ontario residence was inferred from duration of having a health card 5 
and was categorized into: 0 to <5, 5 to <10 and >10 years.  Using standard ICD-9 (prior to 2002) 6 
and ICD-10 (2002 onwards) code clusters, we identified history of stroke or transient ischemic 7 
attack (TIA), atrial fibrillation, hypertension, MI, coronary artery disease, and peripheral 8 
vascular disease (PVD).   9 
 The Charlson comorbidity index (CCI) was calculated using all diagnosis codes and types 10 
from all hospitalizations during the two year period prior to and including the index admission, 11 
using <25 available ICD-9 and ICD-10 codes for each hospitalization.  Since all participants in 12 
this analysis had diabetes, the diabetes indicators were excluded from our CCI calculation.  The 13 
CCI was dichotomized into <2  versus >2, as in previous research.15 14 
Only patients >65 years of age had complete information on prescription medication use.  15 
Baseline medication was defined as any prescription medication use within a 120-day window 16 
after the index stroke discharge, and medication classes included diabetic, statin, and anti-17 
hypertensive medications as well as warfarin.  Aspirin, which is available over-the-counter, had 18 
incomplete capture; hence, antiplatelet medication use was not adjusted for in the sensitivity 19 
analyses.   20 
 21 
Longitudinal follow-up 22 
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Outcomes were: death, any-cause readmission, stroke/TIA readmission, MI readmission, stroke 1 
or MI readmission, and a composite of death or any-cause readmission.  To create these 2 
outcomes, hospital readmissions for the following were assessed: recurrent stroke/TIA (ICD-10 3 
code I63 [excluding I63.6], I64, H34.0, H34.1, G45 [excluding G45.4], H34.0), intracerebral 4 
hemorrhage (I61), recurrent CAD including MI (acute MI, codes I21, I22; unstable angina, code 5 
I20) and cardiac procedures (coronary artery bypass graft and percutaneous cardiac intervention).     6 
 7 
Statistical analysis 8 
Baseline characteristics were reported in the overall sample and stratified by sex.  We calculated 9 
proportions for categorical variables and means and medians for continuous variables. Incidence 10 
was calculated as the incidence of each outcome per 100 person-years (with 95% confidence 11 
intervals), reported by age and sex subgroups.  Two significance tests were performed using a 12 
Poisson regression model: one for the group comparison within each stratum, and the other for 13 
the overall test of significance of that stratum.  14 
For all readmission outcomes (excluding death), a competing risk model proposed by 15 
Fine and Gray16 was used to estimate the hazard ratio and 95% CI of outcomes, with death 16 
defined as the competing risk.  For the outcome of death, Cox proportional hazards models were 17 
used to estimate the hazard ratio and 95% CI.  Models included demographic variables (age, sex, 18 
and income) and vascular risk factors (hypertension, atrial fibrillation, stroke or TIA, MI, CAD, 19 
PVD, and CCI).  A sensitivity analysis was performed among those aged >65 years, among 20 
whom medication use was adjusted for and categorized into anti-hypertensive medication use, 21 
diabetes medication use, statin use, and warfarin use.  All analyses were performed with SAS 22 
version 9.3 (SAS Institute Inc, Cary, NC). 23 
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RESULTS 1 
Out of 84,731 index ischemic stroke admissions during the study time period, 29,752 had 2 
diabetes prior to index admission and were included.  After applying exclusions (age <18 years; 3 
death during index admission; death after index discharge but before any readmissions), the final 4 
sample consisted of 25,495 individuals.  Median follow-up time was 3.2 years.  5 
 Table 1 shows baseline characteristics in the entire sample (n=25,495) and by sex (11,902 6 
females and 13,593 males). Compared to males, females were older and more frequently from 7 
lower neighborhood income quintiles. Females more often had history of prior stroke or TIA, 8 
atrial fibrillation, and hypertension but less often had history of MI, CAD or PVD; females had 9 
lower CCI scores but longer average length of hospital stay. In those aged ≥65 years, females at 10 
baseline were significantly less often taking diabetic or statin medications.  11 
There were 12,435 deaths during follow-up.  The overall frequencies of outcomes by 12 
time interval are listed in Table 1. The unadjusted incidence of death was higher among females 13 
(14.08 per 100 person-years, 95% CI 13.73-14.44 vs. 11.89, 95% CI 11.60-12.19 among males) 14 
and there were higher rates of death among higher age groups (Table 2). Kaplan-Meier curves 15 
showed lower survival probability for females compared to males (p<0.0001) (Figure 1A). After 16 
adjusting for age, income, vascular risk factors, and CCI, women had lower risk of death 17 
compared to men (HR 0.95, 95% CI 0.92-0.99, Table 3). Among those ≥65 years old with or 18 
without adjustment for medications, a similar finding of lower risk of death among females was 19 
seen (HR 0.93, 95% CI 0.89-0.97 and HR 0.93, 95% CI 0.90-0.97, respectively).  20 
There were 17,406 any-cause readmissions during follow-up, of which 3,794 were for 21 
stroke and 2,512 for MI. The unadjusted incidence rate of readmission for any cause or for stroke 22 
was similar by sex (Table 2). There was higher unadjusted incidence among males for 23 
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readmission due to MI (1.99, 95% CI 1.89-2.10 vs. 1.58, 95% CI 1.49-1.68 among females).  1 
There was a pattern of increased incidence of death and lower incidence of readmissions for 2 
stroke, MI, and stroke or MI among successively higher age categories, probably reflecting the 3 
competing risk of death for stroke and MI (Table 2). Kaplan-Meier curves showed a similar 4 
survival probability for males and females of any readmission (Figure 1B) and stroke 5 
readmission (Figure 2A), but a higher risk of MI readmission among males (Figure 2B).   6 
In multivariable competing risk models, females had a lower risk of readmission for any 7 
event (0.96, 95% CI 0.93-0.99, Table 3). There was no sex difference in risk of readmission for 8 
stroke, but females had a lower risk of MI readmission compared to males (0.88, 95% CI 0.81-9 
0.95). Among those age ≥65 years with and without adjustment for medication usage, risk of 10 
readmission for any event remained lower in females but risk of MI readmission was no longer 11 
different by sex.  12 
 13 
DISCUSSION 14 
In this population-based, retrospective study using administrative linkage with full population 15 
coverage for the province of Ontario, we found that women with diabetes, compared to men, had 16 
higher unadjusted mortality and risk of readmission for any cause or death following an incident 17 
stroke but lower risk of readmission for MI. Unadjusted readmission rates for any cause and for 18 
stroke were similar by sex. Diabetic female patients with incident stroke were older and from a 19 
lower socioeconomic status. They were more likely to have hypertension and atrial fibrillation 20 
but less likely to have prior MI, CAD, or PVD.  They were also less likely to be taking diabetic 21 
and statin medications at baseline and had a longer average length of hospital stay during the 22 
incident stroke, suggesting either differences in disease severity or disparities in optimal 23 
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treatment by sex.  These differences likely accounted for the unadjusted mortality difference seen 1 
by sex, because in adjusted models females had lower risk of death and lower risk of any-cause 2 
readmissions compared to males, although the increased risk of MI among males persisted after 3 
adjustment. Readmission rates for stroke remained similar between males and females in 4 
adjusted models. Also, as expected, there was a higher risk of mortality and lower risk of 5 
readmission with increasing age, likely due to the competing risk of death. 6 
The impact of traditional cardiovascular risk factors varies by sex, especially for smoking 7 
(which carries a 25% greater risk for coronary heart disease among women than men17, 18) and 8 
diabetes.1, 2, 17, 18 In addition to traditional risk factors, there are risk factors specific to women, 9 
including gestational hypertension and pre-eclampsia, gestational diabetes, and placental 10 
disorders such as intrauterine growth restriction and stillbirth.17, 19-21 Polycystic ovarian 11 
syndrome, the most common female endocrine disorder, results in insulin resistance and 12 
development of metabolic syndrome.22 Oral contraceptive pills, used by 82% of sexually ever-13 
active women, are associated with elevated risk of venous thrombosis, MI and ischemic stroke 14 
from a presumed pro-coagulant effect.18 Systemic autoimmune collagen vascular diseases, such 15 
as systemic lupus erythematous and rheumatoid arthritis, are more common in females and lead 16 
to accelerated atherosclerosis and progression to heart disease.20, 21 Depression is twice as 17 
common in women and associated with a 70% risk for heart disease; it can lead to non-adherence 18 
with diet, medications, and follow-up. 20 19 
Social support and self-reported quality of life have also been reported to be lower in 20 
diabetic women.23, 24 Prior studies show that women have lower socioeconomic status and lower 21 
access to preventative measures and treatments for diabetes.7, 25 There are also treatment 22 
disparities – women are less likely to be prescribed medications for modifiable risk factors and, 23 
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even when undergoing treatment, they are treated less effectively.20, 22, 26, 27 Our findings also 1 
reflect this female socioeconomic disadvantage as well as lower medication usage, despite 2 
universal health coverage.  3 
Prior studies of sex differences in outcomes among diabetic stroke patients have been in 4 
smaller samples, focused on mortality, and with limited control of socioeconomic status and 5 
medication usage.8-10 In a Spanish prospective single center stroke registry of 561 diabetic stroke 6 
patients, there was higher mortality among women but similar stroke recurrence rates by sex.8 7 
Elevated female mortality and similar stroke recurrence rates by sex were also reported in a 8 
single-center Chinese study of 2360 diabetic stroke patients.10 In a Swedish population-based 9 
study involving 2549 diabetic stroke patients under age 75 years, there was also higher mortality 10 
noted in females; however readmissions were not assessed.9   11 
Our study included over 25,000 diabetic stroke patients and provides reliable evidence 12 
that women have higher mortality after stroke. We demonstrated that this difference is not 13 
present after adequate adjustment, and women actually have a lower age-adjusted risk for 14 
mortality.  This finding is in agreement with a recent meta-analysis using 16,957 pooled 15 
individual participant data from 13 population-based stroke incidence studies from Europe, 16 
Australia, South America, and the Caribbean; it reported a lower crude survival rate in women at 17 
1 and 5 years, which was reversed after adjustment.28 The 5-year pooled estimates had 18 
significant heterogeneity because few studies had follow-up beyond 1 year and there was 19 
missing data across studies, particularly on stroke risk factors such as diabetes (only 5 out of 13 20 
studies reported diabetes status, n=667). Our current report consist of more patients than all 13 21 
studies combined and provides confirmation that female sex, by itself, is not responsible for 22 
increased mortality after stroke in those with diabetes. Beyond mortality outcomes, we also 23 
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demonstrate that there is no sex difference in stroke readmission risk, but males are at higher risk 1 
of readmission for MI. To our knowledge, there have been no prior studies among diabetic 2 
patients with incident stroke reporting the effect of sex and MI vs stroke readmissions. 3 
We found that men had higher risk of MI readmission, suggesting a possible sex-specific 4 
sensitivity to different diabetes-related complications that has been previously demonstrated.27 5 
Men, compared to women, have been reported to have higher coronary atheroma burden, more 6 
diffuse endothelial dysfunction, more severe structural abnormalities in the epicardial coronary 7 
arteries, and more vulnerable plaques.29  Young women are at lower risk of cardiovascular death, 8 
MI, and stroke compared to males, presumably from the cardiovascular protective effects of 9 
estrogen.20, 29, 30 However, the risk profile reverses after menopause with a 10-fold rise in 10 
cardiovascular disease in women compared to a 4.5-fold rise in men of similar age.20, 29, 30 The 11 
protective effects of estrogen likely explains the disappearance of the elevated MI readmission 12 
risk when the sample is restricted to those above age 65, with or without adjustment for 13 
medication usage. Interestingly, this same protective effect was not seen for stroke readmission 14 
in analyses of the unadjusted, adjusted, and age >65 subgroup models. This suggests that 15 
diabetes in pre-menopausal women may blunt the protective effects of estrogen to varying 16 
degrees which may be organ specific.17, 20, 30, 31  17 
 This study attempts to overcome several limitations of prior studies in the area of sex 18 
differences after ischemic stroke.  Due to universal health coverage in Ontario, the sample is 19 
unprecedented in that it includes all adults with diabetes and index ischemic stroke in a large 20 
Canadian province, not just patients from a single center or a population sample.  Hence, this 21 
results in extensive population coverage over a long follow-up period with limited selection bias. 22 
Lack of power to detect sex differences is not a concern.  Also, due to the unique linking among 23 
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different databases, adjustment for the important confounders of socioeconomic status and 1 
medication use was possible.   2 
   There are limitations associated with the usage of administrative and claims-based data, 3 
which may be prone to misclassification and inaccuracy.  For example, sample selection using 4 
ICD code I64, “stroke, not specified as hemorrhagic or infarct”, could possibly capture stroke-5 
types other than ischemic stroke. However, the sensitivity and specificity of diagnosis based on 6 
ICD-10-based codes has been shown to be excellent.  We only have data on events that resulted 7 
in readmission; therefore some events such as TIA may be missed if patients were not admitted 8 
to the hospital. Data on stroke characteristics, such as subtype, severity, location, size, and 9 
discharge handicap were not available.  Similarly, data was available on duration of diabetes but 10 
not on severity of diabetes as assessed by hemoglobin A1c levels. We were able to control for 11 
diabetic, statin and anti-hypertensive medication but could not assess for aspirin usage as it is 12 
available over the counter and therefore could not be reliably controlled. Aspirin’s role in 13 
preventing cardiovascular events in diabetic women is uncertain.22  There is insufficient evidence 14 
that aspirin has a sex-specific cardiovascular impact, and further study is indicated.  15 
Cardiovascular prevention may need to be tailored according to sex, and some studies have 16 
suggested differential effectiveness of interventions by sex.32, 33 A structured personalized 17 
approach may be more effective for women compared to men, but more research is needed.23 18 
In summary, we demonstrated that diabetic female patients have higher mortality after 19 
incident stroke, but female sex was not an independent risk factor. Contrary to previous studies, 20 
female sex was associated with lower mortality after adjustment for vascular risk factors, 21 
demographics, socioeconomic status, and medication usage.  22 
    23 
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Table 1. Baseline characteristics of sample and numbers of outcomes* 
Variable Entire 
Sample 
Female Male p-value 
Number of participants 25495 11902 (46.7) 13593 (53.3)  
Baseline characteristics:     
Age, mean (SD) 73.4 (11.6) 75.6 (11.5) 71.5 (11.3) <0.001 
Neighborhood income: 
   1st quintile (lowest) 
   2nd quintile 
   3rd quintile 
   4th quintile 
   5th quintile (highest) 
 
6438 (25.3) 
5841 (22.9) 
4896 (19.2) 
4449 (17.5) 
3871 (15.2) 
 
3152 (26.5) 
2791 (23.4) 
2277 (19.1) 
1940 (16.3) 
1742 (14.6) 
 
3286 (24.2) 
3050 (22.4) 
2619 (19.3) 
2509 (18.5) 
2129 (15.7) 
<0.001 
Diabetes duration: 
   0 to <3 years 
   3 to <6 years 
   >6 years 
 
5983 (23.5) 
3683 (14.4) 
15829 (62.1) 
 
2780 (23.4) 
1683 (14.1) 
7439 (62.5) 
 
3203 (23.6) 
2000 (14.7) 
8390 (61.7) 
0.337 
Duration of residence in Ontario: 
   0 to <5 years 
   5 to <10 years 
   >10 years 
 
462 (1.8) 
629 (2.5) 
24404 (95.7) 
 
203 (1.7) 
291 (2.4) 
11408 (95.8) 
 
259 (1.9) 
338 (2.5) 
12996 (95.6) 
0.477 
History of stroke or TIA 2031 (8.0) 984 (8.3) 1044 (7.7) 0.072 
History of atrial fibrillation 4614 (18.1) 2501 (21.0) 2113 (15.5) <0.001 
History of hypertension 16161 (63.4) 7848 (65.9) 8313 (61.2) <0.001 
History of MI 2575 (10.1) 1105 (9.3) 1470 (10.8) <0.001 
History of CAD 5619 (22.0) 2424 (20.4) 3195 (23.5) <0.001 
History of PVD 1257 (4.9) 476 (4.0) 781 (5.7) <0.001 
Charlson index score: 
   0-1 
   >2 
 
6801 (26.7) 
18694 (73.3) 
 
3268 (27.5) 
8634 (72.5) 
 
3533 (26.0) 
10060 (74.0) 
0.008 
 
Length of hospital stay, mean (SD) 16.6 (26.7) 17.8 (27.6) 15.5 (25.8) <0.001 
     
Overall frequency of outcomes:     
Death 12435 (48.8) 6115 (51.4) 6320 (46.5) <0.001 
Death within:  
   7 days 
   30 days 
   1 year 
   5 years 
 
108 (0.4) 
805 (3.2) 
4517 (17.7) 
10916 (42.8) 
 
63 (0.5) 
467 (3.9) 
2324 (19.5) 
5439 (45.7) 
 
45 (0.3) 
338 (2.5) 
2193 (16.1) 
5477 (40.3) 
 
0.015 
<0.001 
<0.001 
<0.001 
Readmission for any cause 17406 (68.3) 8051 (67.6) 9355 (68.8) 0.044 
Readmission for any cause within:  
   30 days 
   1 year 
   5 years 
 
1706 (6.7) 
9871 (38.7) 
16402 (64.3) 
 
767 (6.4) 
4614 (38.8) 
7621 (64) 
 
939 (6.9) 
5257 (38.7) 
8781 (64.6) 
 
0.139 
0.88 
0.345 
Readmission for any cause or death 20135 (79.0) 9553 (80.3) 10582 (77.8) <0.001 
Readmission for any cause or death 
within: 
   30 days 
   1 year 
 
 
2381 (9.3) 
11799 (46.3) 
 
 
1172 (9.8) 
5681 (47.7) 
 
 
1209 (8.9) 
6118 (45) 
 
0.009 
<0.001 
Readmission for stroke or MI 5876 (23.0) 2647 (22.2) 3229 (23.8) 0.004 
Readmission for stroke or MI within:     
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   30 days 
   1 year 
   5 years 
538 (2.1) 
2591 (10.2) 
5236 (20.5) 
245 (2.1) 
1196 (10) 
2372 (19.9) 
293 (2.2) 
1395 (10.3) 
2864 (21.1) 
0.591 
0.573 
0.025 
Readmission for stroke 3794 (14.9) 1791 (15) 2003 (14.7) 0.484 
Readmission for stroke within: 
   30 days 
   1 year 
   5 years 
 
472 (1.9) 
1808 (7.1) 
3429 (13.4) 
 
212 (1.8) 
867 (7.3) 
1620 (13.6) 
 
260 (1.9) 
941 (6.9) 
1809 (13.3) 
 
0.437 
0.262 
0.48 
Readmission for MI 2512 (9.9) 1036 (8.7) 1476 (10.9) <0.001 
Readmission for MI within: 
   30 days 
   1 year 
   5 years 
 
66 (0.3) 
844 (3.3) 
2149 (8.4) 
 
33 (0.3) 
360 (3) 
899 (7.6) 
 
33 (0.2) 
484 (3.6) 
1250 (9.2) 
 
0.589 
0.017 
<0.001 
CABG or PCI  1076 (4.2) 333 (2.8) 743 (5.5) <0.001 
     
Baseline medications for those aged 
>65 yr: 
    
Number of participants aged >65 yr 19619 (76.9) 9788 (82.2) 9831 (72.3)  
Diabetic medications 11656 (59.4) 5655 (57.8) 6001 (61) <0.001 
Statin medications 12724 (64.9) 6096 (62.3) 6628 (67.4) <0.001 
Warfarin 4248 (21.7) 2189 (22.4) 2059 (20.9) 0.016 
Anti-hypertensive medications 15778 (80.4) 7923 (80.9) 7855 (79.9) 0.065 
*values are number and column percentages in parentheses unless otherwise indicated; TIA=transient 
ischemic attack; MI=myocardial infarction; CAD=coronary artery disease; PVD=peripheral vascular 
disease; CABG=coronary artery bypass graft surgery; PCI=percutaneous coronary intervention; 
NA=specific values not reported due to identifiability with small cell sizes; IQR=interquartile range 
 
 
17 
 
Table 2. Incidence rate of outcomes per 100 person-years, by subgroups of sex and age 
Outcome Overall rate (95% CI) Rate among females (95% CI) Rate among males (95% CI) p-value 
By sex:     
Death 12.88 (12.65-13.11) 14.08 (13.73-14.44) 11.89 (11.60-12.19) <0.0001 
Readmission for any cause 26.60 (26.00-27.22) 26.20 (25.33-27.10) 26.95 (26.12-27.81) 0.2 
Readmission for any cause or 
death 
39.30 (38.49-40.13) 41.71 (40.47,  43.00) 37.35 (36.29-38.44) <0.0001 
Readmission for stroke 2.86 (2.77-2.95) 2.90 (2.76-3.03) 2.82 (2.70-2.95) 0.4 
Readmission for MI 1.80 (1.73-1.87) 1.58 (1.49-1.68) 1.99 (1.89-2.10) <0.0001 
Readmission for stroke or MI 4.77 (4.65-4.90) 4.59 (4.42-4.77) 4.94 (4.77-5.11) 0.006 
     
By age group: Overall rate (95% CI) Rate among 18-64 yr 
olds (95% CI) 
Rate among 65-79 yr 
olds (95% CI) 
Rate among 80+ yr 
olds (95% CI) 
p-value 
Death 12.88 (12.65-13.11) 4.56 (4.31-4.82) 11.20 (10.89-11.51) 24.67 (24.06-25.29) <0.0001 
Readmission for any cause 26.60 (26.00-27.22) 21.02 (19.94-22.15) 28.85 (27.88-29.85) 27.81 (26.77-28.89) <0.0001 
Readmission for any cause or 
death 
39.30 (38.49-40.13) 23.39 (22.27-24.57) 37.73 (36.57-38.93) 59.57 (57.67-61.53) <0.0001 
Readmission for stroke 2.86 (2.77-2.95) 3.12 (2.92-3.34) 2.95 (2.82-3.09) 2.58 (2.44-2.73) <0.0001 
Readmission for MI 1.80 (1.73-1.87) 2.17 (2.00-2.34) 2.02 (1.91-2.14) 1.32 (1.22-1.42) <0.0001 
Readmission for stroke or MI 4.77 (4.65-4.90) 5.34 (5.07-5.63) 5.13 (4.94-5.32) 4.03 (3.84-4.22) <0.0001 
*MI=myocardial infarction; CI=confidence interval 
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Table 3. Multivariable models of outcomes  
 Competing risk models with death as competing risk Cox regression 
Outcome Any event Stroke MI Stroke or MI Death 
Variable HR  
(95% CI) 
p-value HR  
(95% CI) 
p-value HR  
(95% CI) 
p-value HR  
(95% CI) 
p-value HR  
(95% CI) 
p-value 
Whole sample** 
Age 1.01  
(1.00-1.01) 
<0.0001 0.99  
(0.99-0.99) 
<0.0001 0.99  
(0.98-0.99) 
<0.0001 0.99  
(0.99-0.99) 
<0.0001 1.06  
(1.06-1.06) 
<0.0001 
Female sex† 0.96  
(0.93-  0.99) 
0.004 1.05  
(0.98-1.12) 
0.2 0.88  
(0.81-0.95) 
0.001 0.98  
(0.93-1.03) 
0.4 0.95 
(0.92-0.99) 
0.01 
 
Among those >65 yr without adjustment for medications** 
Age 1.00  
(0.99-1.00) 
0.02 0.98  
(0.98-0.99) 
<0.0001 0.97  
(0.96-0.98) 
<0.0001 0.98  
(0.98-0.98) 
<0.0001 1.07  
(1.06-1.07) 
<0.0001 
Female sex† 0.94  
(0.91-0.97) 
0.0006 1.06  
(0.98-1.14) 
0.1 0.93  
(0.84-1.02) 
0.1 1.01  
(0.95-1.07) 
0.7 0.93  
(0.90-0.97) 
0.0005 
 
Among those >65 yr with adjustment for medications@ 
Age 1.00  
(1.00-1.00) 
0.6 0.99  
(0.98-0.99) 
<0.0001 0.98  
(0.97-0.98) 
<0.0001 0.98  
(0.98-0.99) 
<0.0001 1.06  
(1.06-1.06) 
0.0001 
Female sex† 0.94  
(0.91-0.97) 
0.0004 1.06  
(0.98-1.14) 
0.1 0.92  
(0.84-1.02) 
0.1 1.01  
(0.95-1.07) 
0.8 0.93  
(0.89-0.97) 
0.0002 
MI=myocardial infarction; HTN=hypertension; CAD=coronary artery disease; PVD=peripheral vascular disease; †male sex as referent;**models 
are adjusted for: income, hypertension, atrial fibrillation, stroke or TIA, MI, CAD, PVD, and Charlson score; @models are adjusted for: income, 
hypertension, atrial fibrillation, stroke or TIA, MI, CAD, PVD, Charlson score, anti-hypertensive medication use, diabetes medication use, statin 
use, and warfarin use 
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Figure 1A: Kaplan-Meier survival curve stratified by sex  
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Figure 1B: Kaplan-Meier curves of probability of survival free of readmission, stratified by sex 
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 Figure 1C: Kaplan-Meier curves of probability of survival free of readmission or death, stratified by sex 
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Figure 2A: Kaplan-Meier curves of probability of survival free of stroke readmission, stratified by sex 
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Figure 2B: Kaplan-Meier curves of probability of survival free of myocardial infarction readmission, stratified by sex 
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Figure 2C: Kaplan-Meier curves of probability of survival free of stroke or myocardial infarction readmission, stratified by sex 
  
 
